Organic Active Ingredients TRIZ Cases

Mixed solvent crystallization resolves amorphous polymorphism in morphinan derivatives, ensuring high purity and consistent potency.

Formula I compounds inhibit Mcl-1 protein to promote apoptosis, resolving the contradiction between cell survival and programmed death.

Optimized imidazopyrrolopyridine structures limit systemic absorption to reduce adverse effects while maintaining local therapeutic efficacy.

Film-forming chitosan derivatives increase nail growth rate by 15-48% to shorten treatment duration for onychomycosis.

Intermittent glucocorticoid receptor modulator dosing combined with taxane chemotherapy extends progression-free survival in platinum-resistant ovarian cancer.

Hyaluronic acid derivatives modify the extracellular matrix micro-environment to stimulate cell differentiation.

Avocado-derived C7 sugars aggregate yeasts to block skin invasion, avoiding resistance and adverse effects common with conventional antifungals.

Wet granulation creates high-load dexamethasone tablets that improve patient compliance with recommended dosing regimens.

Rod-shaped sample transfer tool coated with active substances binds inhibitors during nucleic acid transfer.

Optimized ligand parameters resolve low binding affinity issues, enabling accurate diagnosis and monitoring of Parkinson's disease progression.

Merging multiple nutrients into a single thiol-containing alkyl fatty acid formulation resolves bioavailability contradictions to reduce insulin resistance.

Reducing oligopeptide linkers to single asparagine residues maintains high antitumour efficacy while improving stability in healthy organ lysosomes.

XL-647 targets multiple kinases to treat polycystic kidney disease, overcoming single-target limitations.

Segmentation and intermediary principles resolve systemic toxicity by confining drug release to the tumor site while maintaining circulation stability.

Disposable wipe impregnated with lidocaine and sanitizers reduces skin irritation and infection risk during tattooing.

Isolated isoquinoline alkaloids from Aspergillus insuetus treat drug-resistant focal seizures while reducing adverse effects.

MMP-cleavable VDA prodrugs achieve selective tumor activation, reducing systemic toxicity while enhancing anti-cancer efficacy.

Adjusting HPMCAS particle size to 70-300 μm resolves the trade-off between powder flowability and drug miscibility in hot-melt extrusion.

Trichloroacetylation of 10-deacetylbaccatine III enables silica gel chromatographic separation from stubborn analogues, achieving over 99% purity.

Antisense oligonucleotide conjugated with N-acetyl-D-galactosamine targets hepatic cells to correct mutated mRNA splicing.

2-Fucosyl-lactose decreases serum corticosterone levels by modulating the hypothalamic pituitary adrenal response, avoiding synthetic drug complications.

Rheologically tuned oil-in-water gel emulsion adheres to biomaterials and prevents inflammation without sticking to surgical gloves.

Bicyclic sulphonamides inhibit NAAA and activate the Nrf2 pathway, resolving safety risks from reactive compounds while treating neurodegenerative diseases.

Segmented prodrugs activate within tumors via proteolytic cleavage, reducing normal tissue toxicity while maintaining high tumor concentrations.

Phosphate reagents and acid catalysts synthesize nucleoside triphosphates, bypassing HPLC purification to enable scalable gram-level production.

Disulfide-crosslinked lipoic acid nanoparticles improve insulin sensitivity and treat complications without injection risks.

Selective deuteration at specific molecular positions improves metabolic profiles while reducing synthesis complexity compared to complete deuteration.

Chemical modifications including 2-O-methyl and GalNAc conjugation resolve the contradiction between gene silencing activity and in vivo stability.

Novel imidazoquinoline compounds act as potent inducers of human interferon-alpha for treating allergic and infectious diseases.

An adhesive layer combines lactic acid for drug permeation with magnesium aluminometasilicate to absorb sweat and maintain adhesiveness in wet conditions.

Pyrazole derivatives with specific substituent patterns inhibit mGlu5 receptors to treat neurological disorders and chronic pain.

A PRMT5 inhibitor blocks AR transcriptional activity in TMPRSS2:ERG positive prostate cancer cells.

Red and gold interference pigments in the foundation shift hue based on underlying skin undertones, resolving shade matching uncertainty.

Low-dose brimonidine achieves preferential vasoconstriction while minimizing rebound hyperemia.

Perfluoroalkylated compounds modify the CAP-group of type II kinase inhibitors to engage diverse subpockets.

Replacing batch reactors with a continuous flow system resolves explosion hazards and mass transfer inefficiencies during oxidative N-demethylation.

Selective JAK and IRAK kinase inhibitors modulate cytokine signaling pathways, reducing inflammatory levels to prevent severe CRS complications.

GPR40 agonist compounds modulate insulin release to preserve islet activity and control blood sugar levels in type 2 diabetes treatment.

iRNA compositions target C5 transcripts via RISC cleavage, reducing eculizumab dosage frequency and treatment costs for PNH.

A synergistic blend of N-(3-Aminopropyl)-1,4-butanediamine and a histidine-containing dipeptide activates TFEB gene expression to promote intracellular clearance.

Oral small-molecule TLR7 agonists replace lifelong nucleoside analogues by triggering host immunity for finite-duration functional cures.